Small breast tumours might need more treatment

Little breast tumours that seemed cured after surgery are more likely to come back if they are the type known as HER2 positive, US researchers reported.They said women who have these types of tumours may need extra treatment with drugs such as...

Little breast tumours that seemed cured after surgery are more likely to come back if they are the type known as HER2 positive, US researchers reported.
They said women who have these types of tumours may need extra treatment with drugs such as Herceptin – which is not standard practice now.
"Most physicians do not treat these small tumours with Herceptin," Dr Ana M. Gonzalez-Angula of the MD Anderson Cancer Centre in Houston, who led the study, said.
After five years, 23 per cent of patients with tiny tumours one cm (half an inch) or smaller whose cancer was HER2 positive had tumors come back after surgery, Dr Gonzalez-Angula told the San Antonio Breast Cancer Conference.
Her team looked at more than 1,300 women between 1990 and 2003. Ten per cent had HER2 tumours and they had a much higher likelihood the cancer would come back than those with the more common oestrogen receptor positive tumours or those with so-called triple negative tumours.
These three types of tumour each have a different mutation that drives the cancer. Oestrogen receptor positive breast tumours are the easiest to treat, with a range of drugs that affect the hormone.
The women, with an average age of 57, had 2.68 times the risk their cancer would come back after surgery if they had HER2-positive tumors than the other patients, Dr Gonzalez-Angula told the meeting.
HER2-positive tumours had been more difficult to treat but Herceptin is a genetically engineered antibody – an immune system molecule – that homes in on that particular mutation.

Source: Reuters

Sign up to our free newsletters

Get the best updates straight to your inbox:

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.